FDA looks at pulling speedy approvals for three cancer drugs
pharmaphorum
APRIL 27, 2021
FDA advisors will scrutinise three cancer immunotherapies granted conditional approvals at a three-day meeting this week, to see if they should stay on the market. . Briefing documents published by the FDA ahead of the meeting suggest that discussion will focus on ongoing trials that may serve as alternative confirmatory studies.
Let's personalize your content